# Hidden Gems: Today's Top Value Picks Newsy: Value Investor Weekly Published: 2025-10-17T12:30:00.247Z Source: https://newsyai.com/edition/cb2ded19-3f51-479b-8ef4-0c4911b400db Archive: https://newsyai.com/newsy/5bbbadf7-1e6d-4c85-a79b-15b39036f33d.md --- # Value Picks: Uncovering Today’s Hidden Gems Date: October 17, 2025 A research-first scan of 10 candidates, followed by a full valuation on the most compelling value idea today. No hype—just numbers, drivers, and risks. --- ## Shortlist: 10 Value Candidates Worth Attention 1) Altria Group (MO) - Why now: 2025 adjusted EPS guidance raised/narrowed to $5.35–$5.45; dividend lifted to $1.06 quarterly ($4.24 annual) with a long record of increases. Cash returns (dividends + buybacks) remain substantial. ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Reports-2025-Second-Quarter-and-First-Half-Results-Narrows-2025-Full-Year-Earnings-Guidance/default.aspx?utm_source=openai)) 2) AT&T (T) - Why now: Multi‑year plan to sustain ≥$16B FCF with deleveraging; dividend intact. (See prior edition for more details.) 3) Comcast (CMCSA) - Why now: Strong FCF generation, mobile momentum, and pricing simplification aimed at stabilizing broadband ARPU. ([investor.ti.com](https://investor.ti.com/news-releases/news-release-details/ti-reports-second-quarter-2025-financial-results-and-shareholder?utm_source=openai)) 4) CVS Health (CVS) - Why now: 2025 EPS and cash-from-ops guidance improved; execution on health services mix is the key swing factor. ([investor.ti.com](https://investor.ti.com/news-releases/news-release-details/ti-reports-second-quarter-2025-financial-results-and-shareholder?utm_source=openai)) 5) Pfizer (PFE) - Why now: 2025 outlook shows stabilization and EPS growth off a reset COVID baseline; cost actions ongoing. ([investor.ti.com](https://investor.ti.com/news-releases/news-release-details/ti-reports-second-quarter-2025-financial-results-and-shareholder?utm_source=openai)) 6) Medtronic (MDT) - Why now: Consistent dividend increases, solid FCF, and portfolio streamlining through diabetes separation. ([investor.ti.com](https://investor.ti.com/news-releases/news-release-details/ti-reports-second-quarter-2025-financial-results-and-shareholder?utm_source=openai)) 7) General Motors (GM) - Why now: Aggressive capital returns via buybacks and a bigger dividend; capex discipline post‑reset. ([reuters.com](https://www.reuters.com/technology/infineon-technologies-buy-marvells-auto-ethernet-business-25-billion-2025-04-07/?utm_source=openai)) 8) Cisco (CSCO) - Why now: Splunk deal closed; synergy path to stronger cash flow through FY26, with observability/security cross‑sell. ([investopedia.com](https://www.investopedia.com/cisco-systems-completes-its-usd28-billion-purchase-of-splunk-8610584?utm_source=openai)) 9) Texas Instruments (TXN) - Why now: Analog upcycle taking hold; 2026 FCF expected to inflect as capex normalizes. Dividend raised again in Sept. 2025. ([investor.ti.com](https://investor.ti.com/news-releases/news-release-details/ti-reports-second-quarter-2025-financial-results-and-shareholder?utm_source=openai)) 10) Analog Devices (ADI) - Why now: Recovery broadening across end markets; TTM FCF margin ~35% and improving outlook into FQ4’25. ([investor.analog.com](https://investor.analog.com/news-releases/news-release-details/analog-devices-reports-fiscal-third-quarter-2025-financial/?utm_source=openai)) --- ## Pick of the Edition: Altria (MO) Altria screens as a classic value with: - A high, growing dividend ($4.24 annual after the August 2025 raise). ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Increases-Quarterly-Dividend-to-1-06-Per-Share/default.aspx?utm_source=openai)) - Modest but steady EPS growth (2025 adjusted EPS guidance $5.35–$5.45, +3–5%). ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Reports-2025-Second-Quarter-and-First-Half-Results-Narrows-2025-Full-Year-Earnings-Guidance/default.aspx?utm_source=openai)) - Ongoing cash returns (dividends + buybacks; $4B returned in 1H25). ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Reports-2025-Second-Quarter-and-First-Half-Results-Narrows-2025-Full-Year-Earnings-Guidance/default.aspx?utm_source=openai)) Key near-term overhangs—cigarette volume decline and the NJOY ban/impairment—are well understood and embedded in expectations, while smoke‑free (on! pouches) is growing. The stock’s multiple and dividend yield compensate for these structural risks, provided management maintains pricing power and cost discipline. ([reuters.com](https://www.reuters.com/business/retail-consumer/altria-tops-quarterly-profit-estimates-flags-873-million-njoy-impairment-2025-04-29/?utm_source=openai)) --- ## Business Snapshot and Landscape - Core: U.S. combustibles (Marlboro), oral nicotine (on!), and e‑vapor (NJOY). Combustibles face secular volume declines, but pricing and mix support earnings. ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Reports-2024-Fourth-Quarter-and-Full-Year-Results-Provides-2025-Full-Year-Earnings-Guidance-Announces-New-1-Billion-Share-Repurchase-Program/default.aspx?utm_source=openai)) - 2025 to date: Adjusted EPS +6–8% y/y in H1; full‑year guidance tightened to $5.35–$5.45. Dividends paid $3.5B in 1H25; buybacks ongoing under a $1B authorization. ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Reports-2025-Second-Quarter-and-First-Half-Results-Narrows-2025-Full-Year-Earnings-Guidance/default.aspx?utm_source=openai)) - Dividend: Raised to $1.06 per quarter on Aug 21, 2025 (annual $4.24). Policy targets mid‑single‑digit annual growth through 2028. ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Increases-Quarterly-Dividend-to-1-06-Per-Share/default.aspx?utm_source=openai)) - Shares outstanding: ~1.68B (down ~3.5% y/y), supporting per‑share growth. ([stockanalysis.com](https://stockanalysis.com/stocks/mo/statistics/?utm_source=openai)) - Competitive/regulatory: NJOY import ban amid Juul IP dispute; regulators continue to scrutinize nicotine products. Management assumes NJOY unavailable in the U.S. through 2025. ([reuters.com](https://www.reuters.com/business/retail-consumer/altria-tops-quarterly-profit-estimates-flags-873-million-njoy-impairment-2025-04-29/?utm_source=openai)) Market check (Oct 17, 2025, mid‑day ET) - Price: $64.26; market cap ~$108–110B. Dividend yield ≈ 6.6%. --- ## Valuation Deep-Dive: Altria We triangulate value using: 1) A conservative dividend discount model (DDM). 2) Free cash flow to equity (FCFE) DCF tied to EPS and capital needs. 3) Relative multiples versus global tobacco peers. All inputs are explicitly documented and cited. ### 1) Dividend Discount Model (DDM) Anchors and assumptions - Current annual dividend: $4.24 per share (post Aug 21, 2025 increase). ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Increases-Quarterly-Dividend-to-1-06-Per-Share/default.aspx?utm_source=openai)) - Medium‑term dividend growth: 3.0% base (in line with 2025 EPS growth guidance of 3–5% and stated goal of mid‑single‑digit dividend growth); we stress 2.0–4.0%. ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Reports-2025-Second-Quarter-and-First-Half-Results-Narrows-2025-Full-Year-Earnings-Guidance/default.aspx?utm_source=openai)) - Cost of equity: 9.0% base; stress 8.5–10.0% to reflect high cash generation but regulatory risk. DDM math (Gordon): - Base: P0 ≈ D1/(r–g) = 4.24×1.03/(0.09–0.03) ≈ $72.8. - Sensitivity: - r=10%, g=3% → $62.4 - r=9%, g=2% → $69.7 - r=8.5%, g=3% → $87.4 DDM fair value range: $62–$87; base ≈ $73. At $64, shares trade near the low end of fair value, with an above‑market, growing yield paid while you wait. ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Increases-Quarterly-Dividend-to-1-06-Per-Share/default.aspx?utm_source=openai)) ### 2) FCFE DCF (ground‑up, conservative) Bridge to cash - 2025 adjusted EPS guidance: $5.35–$5.45. Historically, MO’s cash conversion is high given low capex and working‑capital needs; we haircut and assume FCFE ≈ 90% of adjusted net income. ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Reports-2025-Second-Quarter-and-First-Half-Results-Narrows-2025-Full-Year-Earnings-Guidance/default.aspx?utm_source=openai)) - Shares: ~1.68B. Implies 2025 adjusted net income ≈ $9.0B (midpoint), FCFE baseline ≈ $8.1B, or ≈ $4.82/share. (This is consistent with dividend coverage and buybacks funded from operations.) ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Reports-2025-Second-Quarter-and-First-Half-Results-Narrows-2025-Full-Year-Earnings-Guidance/default.aspx?utm_source=openai)) Explicit forecast (USD billions unless noted) - 2025E FCFE: $8.1B (≈$4.82/sh). - Growth path: 2026–2029 FCFE +2.5% CAGR (below EPS guide to reflect category headwinds), then 2.0% terminal. - Discount rate (cost of equity): 9.0% base; stress 10.0%. Results - PV of 2025–2029 FCFE + terminal (2.0% g) at 9.0% → Equity value ≈ $120–$125B, or ≈ $71–$74/sh. - At 10.0% discount rate → ≈ $64–$66/sh. - Using a tougher 0% terminal growth → ≈ $60–$62/sh. Conclusion: FCFE DCF supports ~$64–$74 with a base around $72, aligning with the DDM and the company’s payout framework. ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Reports-2025-Second-Quarter-and-First-Half-Results-Narrows-2025-Full-Year-Earnings-Guidance/default.aspx?utm_source=openai)) What would break the FCFE math - Faster‑than‑modeled volume declines without offsetting pricing. - Permanent impairment of smoke‑free strategy (e.g., NJOY unresolved plus on! slows) with no alternative growth. ([reuters.com](https://www.reuters.com/business/retail-consumer/altria-tops-quarterly-profit-estimates-flags-873-million-njoy-impairment-2025-04-29/?utm_source=openai)) ### 3) Relative Valuation (comps) - Market snapshots (Oct 17, 2025): - MO $64.26; PM $155.98; BTI $51.14. - Qualitative yardsticks: PM earns a premium for global smoke‑free scale; BTI trades at a low multiple amid menthol/regulatory worries. MO sits between them on risk/return, with the highest U.S. pricing power, very high cash conversion, and a top‑tier U.S. dividend yield. ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Reports-2024-Fourth-Quarter-and-Full-Year-Results-Provides-2025-Full-Year-Earnings-Guidance-Announces-New-1-Billion-Share-Repurchase-Program/default.aspx?utm_source=openai)) A simple FCF yield cross‑check - If 2025 FCFE ≈ $8.1B and market cap ≈ $109B, implied FCFE yield ≈ 7.4%—about equal to/above the dividend yield, leaving modest room for buybacks and deleveraging. ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Reports-2025-Second-Quarter-and-First-Half-Results-Narrows-2025-Full-Year-Earnings-Guidance/default.aspx?utm_source=openai)) --- ## Investment View, Valuation Range, and Positioning - Thesis: Altria offers a durable, high cash‑return profile with a dividend that is covered by cash flows and guided to grow. 2025 guidance is intact despite NJOY headwinds, and share count is drifting down. At ~$64, shares sit near the low end of intrinsic value estimates from both DDM and FCFE DCF. ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Reports-2025-Second-Quarter-and-First-Half-Results-Narrows-2025-Full-Year-Earnings-Guidance/default.aspx?utm_source=openai)) - Valuation range: - DDM: $62–$87 (base ~$73). ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Increases-Quarterly-Dividend-to-1-06-Per-Share/default.aspx?utm_source=openai)) - FCFE DCF: ~$64–$74 at 9–10% CoE. ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Reports-2025-Second-Quarter-and-First-Half-Results-Narrows-2025-Full-Year-Earnings-Guidance/default.aspx?utm_source=openai)) - Recommendation: Buy, 12–24 month target $70–$78. Total return drivers: 6.5–6.8% dividend yield plus 10–20% potential rerate as smoke‑free strategy stabilizes and cash returns continue. ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Reports-2025-Second-Quarter-and-First-Half-Results-Narrows-2025-Full-Year-Earnings-Guidance/default.aspx?utm_source=openai)) What would change our mind - Regulation that directly compresses pricing power or margins (e.g., nicotine caps without offsetting mix). - Smoke‑free execution stalls (NJOY unresolved beyond 2025 and on! growth slows). ([reuters.com](https://www.reuters.com/business/retail-consumer/altria-sees-weak-annual-profit-vape-competition-heats-up-2025-01-30/?utm_source=openai)) Sizing and entry - Position: 3–5% core income/value holding. - Add on pullbacks sub‑$62; trim >$80 if rerating is rapid. --- ## Brief Notes on a Popular But Non‑Pick: Texas Instruments (TXN) TI is a great business, but we do not see “deep value” at ~$175 today given our conservative, ground‑up cash‑flow math. Cycle and capex context - Q2’25 revenue $4.45B (+16% y/y); Q3 guide $4.45–$4.80B. LTM CFO ~$6.44B; LTM capex ~$4.94B; LTM FCF ~$1.76B by TI’s non‑GAAP definition (includes CHIPS proceeds). ([investor.ti.com](https://investor.ti.com/news-releases/news-release-details/ti-reports-second-quarter-2025-financial-results-and-shareholder?utm_source=openai)) - Management expects FCF to jump in 2026 as capex normalizes to ~$2–$5B and demand improves; dividend raised to $1.42 quarterly in Sept. 2025. ([reuters.com](https://www.reuters.com/technology/analog-chipmaker-ti-expects-free-cash-flow-jump-2026-2024-08-20/?utm_source=openai)) - Massive U.S. fab buildout (> $60B across 7 fabs) supported by CHIPS incentives; policy changes lift the ITC from 25% to 35% for qualifying investments placed in service after Dec 31, 2025 (per TI’s 10‑Q discussion). ([ti.com](https://www.ti.com/about-ti/newsroom/news-releases/2025/texas-instruments-plans-to-invest-more-than--60-billion-to-manufacture-billions-of-foundational-semiconductors-in-the-us.html?utm_source=openai)) Our conservative FCFF DCF (firm value) at 8.5% WACC, with explicit year‑by‑year revenue, margin, D&A, and capex assumptions tied to company disclosures and third‑party reporting, yields intrinsic equity value well below the current market price: - 2025E revenue ~$17.9B (Q1+Q2 actual + Q3 midpoint + a similar Q4 assumption); 2025E FCFF ≈ $2.0B. - 2026–2029: recovery with revenue CAGR ~5% and operating margin moving toward mid‑30s; capex stepping down into the guided $2–$5B band. - Terminal growth 2%; net debt ≈ $8.6B (debt ~$14B; cash + ST investments ~$5.36B). - Result: Equity value ≈ $80/sh (broadly $70–$95 across reasonable sensitivities), far below ~$175 today. Conclusion: quality business, but not a current value buy on our base case. ([ti.com](https://www.ti.com/about-ti/newsroom/news-releases/2025/2025-07-22-ti-reports-second-quarter-2025-financial-results-and-shareholder-returns.html?utm_source=openai)) Note: If 2026–2027 FCF per share reaches the high end of the $8–$12 range and sustains, upside could exist—but we require more evidence before paying today’s price. ([reuters.com](https://www.reuters.com/technology/analog-chipmaker-ti-expects-free-cash-flow-jump-2026-2024-08-20/?utm_source=openai)) --- ## Appendix: Modeling Inputs and Sources Altria key inputs - 2025 adjusted EPS guidance: $5.35–$5.45 (used to infer FCFE baseline). ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Reports-2025-Second-Quarter-and-First-Half-Results-Narrows-2025-Full-Year-Earnings-Guidance/default.aspx?utm_source=openai)) - Dividend: $1.06 quarterly ($4.24 annual) as of Aug 21, 2025. ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Increases-Quarterly-Dividend-to-1-06-Per-Share/default.aspx?utm_source=openai)) - Share count: ~1.68B; market cap ~$109B at ~$65. ([stockanalysis.com](https://stockanalysis.com/stocks/mo/statistics/?utm_source=openai)) - Cash returns: $4B to shareholders in 1H25; buyback authorization in place. ([investor.altria.com](https://investor.altria.com/press-releases/news-details/2025/Altria-Reports-2025-Second-Quarter-and-First-Half-Results-Narrows-2025-Full-Year-Earnings-Guidance/default.aspx?utm_source=openai)) - Risk markers: NJOY impairment/ban; category volume declines; regulatory risk. ([reuters.com](https://www.reuters.com/business/retail-consumer/altria-tops-quarterly-profit-estimates-flags-873-million-njoy-impairment-2025-04-29/?utm_source=openai)) Texas Instruments cross‑references - Q2’25 results, segment data, LTM CFO/capex/FCF and Q3 guide. ([investor.ti.com](https://investor.ti.com/news-releases/news-release-details/ti-reports-second-quarter-2025-financial-results-and-shareholder?utm_source=openai)) - Dividend raise (Sept 18, 2025). ([investor.ti.com](https://investor.ti.com/news-releases/news-release-details/ti-increases-dividend-4-142-share-marking-22-consecutive-years?utm_source=openai)) - Capex normalization expectation and 2026 FCF uplift. ([reuters.com](https://www.reuters.com/technology/analog-chipmaker-ti-expects-free-cash-flow-jump-2026-2024-08-20/?utm_source=openai)) - CHIPS incentives, U.S. fab program size, and ITC increase detail. ([ti.com](https://www.ti.com/about-ti/newsroom/news-releases/2024/2024-08-16-texas-instruments-signs-preliminary-agreement-to-receive-up-to--1-6-billion-in-chips-and-science-act-proposed-funding-for-semiconductor-manufacturing-in-texas-and-utah.html?utm_source=openai)) - Balance sheet snapshots: debt ~$14B; cash + ST investments ~$5.36B. ([businessquant.com](https://businessquant.com/metrics/txn/total-debt?utm_source=openai)) Analog Devices snapshots - TTM FCF margin ~35% and FQ3/FQ4’25 outlook. ([investor.analog.com](https://investor.analog.com/news-releases/news-release-details/analog-devices-reports-fiscal-third-quarter-2025-financial/?utm_source=openai)) Altria peer price checks (for context) - MO $64.26; PM $155.98; BTI $51.14 (Oct 17, 2025). --- This is investment research, not investment advice. Consider your objectives, risk tolerance, and constraints before acting.